The Power of Real-World Data to Detect Adverse Events and Expedite FDA Postmarking Safety Commitments

Verana Ocular Email Header (1)-1

Access Your Copy of the White Paper

To overcome the limitations inherent in traditional clinical trials, researchers increasingly are turning to real-world data (RWD) to provide a picture of a drug’s efficacy and safety. One example is our work with Ocular Therapeutix to satisfy FDA postmarketing safety requirements.


This white paper includes:

  1. Why point-of-care EHR data is a game changer

  2. Details on the Ocular Therapeutix ReSure Sealant Study

  3. FDA and the use of real-world data

Complete the form to access your copy.

Please do not send any Protected Health Information (PHI) when submitting this form. This form is not encrypted and it is not a suitable method for transmitting PHI. Any PHI sent to Verana Health via this form is deemed to be authorized by the subject of the PHI.

Dots Divider